A New Lifeline: Phraxis Begins Trial for Dialysis Graft Device

ST. PAUL, Minn. – January 28, 2026 – Medical device company Phraxis Inc. has initiated a pivotal real-world study for its EndoForce™ Anastomotic Connector, a device designed to address one of the most persistent problems in hemodialysis care. The first procedure in this Post-Approval Study (PAS) was successfully performed at Spartanburg Regional Healthcare System in South Carolina, marking a crucial step from regulatory clearance to proving long-term clinical value for patients with end-stage kidney disease.

For the hundreds of thousands of Americans who rely on hemodialysis to survive, the vascular access site—the port in their arm used for treatment—is quite literally their lifeline. But this lifeline is often fragile. The announcement from Phraxis signals a potential shift in managing this fragility, moving a promising technology into the complex environment of everyday clinical practice.

The Unseen Struggle of Vascular Access

Hemodialysis requires a durable and reliable way to access a patient's bloodstream. While an arteriovenous fistula (AVF), a direct surgical connection of an artery to a vein, is the preferred method, it is not an option for many patients with inadequate veins. For them, an arteriovenous (AV) graft—a synthetic tube connecting an artery to a vein—is the next best alternative.

However, AV grafts have a well-documented history of failure. Research shows that primary patency, or the period a graft remains functional without intervention, can be alarmingly short, with some studies indicating failure rates exceeding 50% within the first year. This high failure rate is not just a medical statistic; it translates into a cycle of repeated procedures, hospitalizations, and a diminished quality of life for patients.

The primary culprit behind this failure is the development of stenosis, or narrowing, at the point where the graft connects to the patient's vein—the graft-to-vein outflow anastomosis. This junction experiences turbulent blood flow and pressure changes that injure the vein wall, triggering a biological response called neointimal hyperplasia. This process causes the vessel to thicken and narrow, restricting blood flow and eventually leading to clotting and complete graft failure. This single point of failure accounts for over 80% of all AV graft complications.

Each failure necessitates an intervention, ranging from balloon angioplasty to clear the blockage to surgical thrombectomy to remove a clot. In many cases, the graft must be abandoned entirely, forcing the patient to undergo another surgery for a new access site and often rely on a high-risk temporary catheter in the interim. This cycle of failure and repair is not only a significant physical and emotional burden on patients but also a major driver of cost for the healthcare system.

A Targeted Solution Beyond Initial Approval

Phraxis aims to break this cycle with the EndoForce™ Anastomotic Connector. The device is specifically engineered to reinforce the graft-to-vein anastomosis, the known weak link in the system. By providing structural support at this critical junction, the connector is designed to normalize blood flow, reduce the stress on the vein wall, and mitigate the biological cascade that leads to stenosis and failure.

The initiation of the Post-Approval Study is arguably as significant as the device's initial FDA clearance. While pre-market pivotal trials are essential for proving a device's basic safety and efficacy in a controlled setting, a PAS is designed to answer a more important question: Does it work consistently and durably in the real world, across a diverse range of patients and clinical practices?

This commitment to generating long-term, real-world evidence was underscored by company leadership. "This milestone reflects our conviction that FDA approval is the foundation, not the finale, of a device's clinical narrative," said Alex Yevzlin, MD, Chief Executive Officer of Phraxis. "Through this study, we are upholding a rigorous commitment to transparency and evidence-based medicine, ensuring that the dialysis community has the longitudinal data necessary to improve patient outcomes."

John Zentgraf, the company's Chief Operating Officer, framed the move in terms of strategic execution. "This first PAS case represents disciplined progress—aligning clinical evidence generation with deliberate operational execution," he stated. "In the MedTech sector, durable innovation is built through this precise intersection of clinical rigor and scalable practice."

From Controlled Trials to Clinical Reality

The choice of Spartanburg Regional Healthcare System and the team led by Dr. Ari Kramer for the inaugural procedure is telling. Such studies are typically launched at centers with recognized expertise in the field. The involvement of a multidisciplinary team specializing in advanced vascular access highlights the complexity of dialysis care and the collaborative effort required to introduce and validate new technologies.

Conducting the study in a real-world setting like Spartanburg Regional allows Phraxis to gather data on a broader patient population than is typically possible in a pre-market trial. It also provides invaluable feedback on procedural techniques, learning curves for surgeons, and the device's performance alongside other common medical treatments. This data is essential for refining best practices and ensuring the technology can be adopted successfully on a larger scale.

Success in this study could fundamentally change the conversation around AV grafts. Instead of being viewed as a temporary and trouble-prone solution, a graft implanted with the EndoForce™ connector could potentially offer durability closer to that of a fistula, expanding the options for patients who are not candidates for a native fistula.

Reshaping the Standard of Care and Market Dynamics

If the Post-Approval Study validates the promise of the EndoForce™ connector, the impact could be profound. A device that significantly extends the functional life of an AV graft would represent a major disruption in the vascular access market. Current interventions for stenosis, such as balloon angioplasty, are often a temporary fix, with restenosis occurring frequently. EndoForce™ offers a proactive, preventative approach rather than a reactive treatment.

The economic implications are equally significant. The costs associated with managing AV graft failure—including surveillance, multiple angioplasty procedures, thrombectomies, hospital stays for access-related infections, and the placement of temporary catheters—are substantial. A device that reduces the frequency of these events could generate considerable cost savings for healthcare systems like Medicare, which covers the vast majority of dialysis patients in the United States.

This potential for both improved clinical outcomes and economic efficiency is a powerful combination that drives market adoption and can establish a new standard of care. Phraxis is betting that by investing in rigorous, transparent, post-market evidence, it can convince surgeons, nephrologists, and healthcare administrators that the upfront investment in the EndoForce™ device is more than offset by the long-term benefits. For the millions who depend on this life-sustaining therapy, the results of this study could mark the beginning of a new, more durable era in dialysis care.